NCCN Pharmacy Updates: Updates in Ovarian Cancer - Putting Together the PARP Puzzle and Understanding a New Therapeutic Target |
1.00 |
02/27/2024 - 12:00am to 08/18/2024 - 12:00am |
Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates |
1.25 |
03/15/2024 - 12:00am to 03/15/2025 - 12:00am |
Perioperative Management of Anticoagulation and Antithrombotic Therapy |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Prophylactic Vaccines/Immunizations for Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
Psychotherapeutic Strategies and Pharmacotherapy Options for Addressing Distress in Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2024 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Targeted Therapy for Biliary Tract Cancers |
1.00 |
12/19/2023 - 12:00am to 12/14/2024 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: Ampullary Adenocarcinoma: Overview of Subtypes and Treatments |
1.00 |
09/21/2023 - 12:00am to 09/13/2024 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: Changing Treatment Paradigms in Chronic Lymphocytic Leukemia |
1.00 |
05/26/2023 - 12:00am to 05/24/2024 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: The Growing Impact of Pharmacogenomics Across the Oncology Landscape |
1.00 |
03/21/2024 - 12:00am to 03/21/2025 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer |
1.00 |
06/09/2023 - 12:00am to 05/31/2024 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Adult Acute Lymphoblastic Leukemia |
1.00 |
12/21/2023 - 12:00am to 12/20/2024 - 11:59pm |
Recorded Presentation from the NCCN Pharmacy Updates: Updates on Targeted Therapy for the Treatment of Thyroid Carcinoma |
1.00 |
06/30/2023 - 12:00am to 06/28/2024 - 12:00am |
Recorded Presentations from the NCCN 2023 Annual Congress: Hematologic Malignancies™ |
|
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |